COVID-19: Anti-parasitic drug Ivermectin eliminates SARS-CoV-2 in cells in 48 hours

Ivermectin shows promise as potential COVID-19 therapy.

Summary: An FDA-approved anti-parasitic drug called Ivermectin appears to inhibit and eliminate SARS-CoV-2 in lab-grown cell cultures within 48 hours. Ivermectin shows promise as potential COVID-19 therapy. However, researchers stress the need for further testing and clinical trials in humans to confirm the effectiveness of the drug and appropriate dosage levels.

Source: Monash University

Monash scientists have shown that an anti-parasitic drug already available around the world can kill the virus within 48 hours.

Scientists from the Biomedicine Discovery Institute (BDI) showed that a single dose of the drug, Ivermectin, could stop the SARS-CoV-2 virus growing in cell culture.

This Monash University-led collaborative study was published in Antiviral Research, a peer-reviewed medical journal Antiviral Research.

Whilst shown to be effective in the lab environment, Ivermectin cannot be used in humans for COVID-19 until further testing and clinical trials have been completed to confirm the effectiveness of the drug at levels safe for human dosing. The potential use of Ivermectin to combat COVID-19 remains unproven, and depends on funding to progress the work into the next stages.

In the study, participants were tested the morning after 5 nights of regular sleep and after 5 consecutive nights of sleep restriction (5 hours a night). The image is in the public domain.

For any medical questions you have about your health, please consult your health care provider.

About this COVID-19 research article

Source:
Monash University
Media Contacts:
Tania Ewing – Monash University
Image Source:
The image is in the public domain.

Original Research: Open access
“The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro”. Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff.
Antiviral Research doi:10.1016/j.antiviral.2020.104787.

Abstract

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

Feel Free To Share This Coronavirus News.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.